Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 12/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | HTR1D | P28221 | 2/20 | 0.36 |
| ▸ | HTR1B | P28222 | 2/20 | 0.36 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2545562 | 0.80 | QPCT (0.63) | QPCT | |
| SCHEMBL2457552 | 0.79 | HTR1D (0.45) | QPCTLTA4HCYP17A1CYP11B1CYP11B2 | |
| SCHEMBL2542024 | 0.77 | QPCT (0.59) | QPCT | |
| SCHEMBL12286798 | 0.77 | QPCT (0.59) | QPCT | |
| SCHEMBL12230697 | 0.77 | QPCT (0.80) | QPCT | |
| SCHEMBL2542450 | 0.77 | IP6K1 (0.43) | QPCTLTA4HCYP17A1CYP11B1CYP11B2 | |
| SCHEMBL2557274 | 0.77 | QPCT (0.68) | QPCT | |
| SCHEMBL2545455 | 0.77 | QPCT (0.55) | QPCT | |
| SCHEMBL2539387 | 0.76 | QPCT (0.54) | QPCT | |
| SCHEMBL2543554 | 0.74 | QPCT (0.59) | QPCT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541596-B2 | Inhibitors | PROBIODRUG AG (DE) | 2013-09-24 | — | — | US | claimed |
| US-8541596-B2 | Inhibitors | PROBIODRUG AG (DE) | 2013-09-24 | — | — | US | disclosed |
| US-8541596-B2 | Inhibitors | PROBIODRUG AG (DE) | 2013-09-24 | — | — | US | disclosed |
| US-8541596-B2 | Inhibitors | PROBIODRUG AG (DE) | 2013-09-24 | — | — | US | disclosed |
| EP-2560953-A2 | NOVEL INHIBITORS | Probiodrug AG (DE) | 2013-02-27 | — | — | EP | disclosed |
| WO-2011131748-A2 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011131748-A2 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2011-10-27 | — | — | WO | disclosed |
| US-20110262388-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2011-10-27 | — | — | US | disclosed |
| US-20110262388-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2011-10-27 | — | — | US | disclosed |
| US-20110262388-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110262388-A1 | NOVEL INHIBITORS | GLUL, QPCT, GLS | QPCT 2/4885LTA4H 1890/4885CYP17A1 1655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.